Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow (FCF).
HIK Free Cash Flow Analysis
Free cash flow, a measure commonly used by analysts to assess a company's profitability, represents the cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
The Free Cash Flow is calculated using a number of methods including using Operating Cash Flow. Following is the formula to calculate Free Cash Flow based on Operating Cash Flow.
Free Cash Flow = Operating Cash Flow - Capital Expenditures
Using above formula to calculate Free Cash Flow for Hikma Pharmaceuticals PLC (HIK), the free cash flow value is 119.00M.
All amounts in USD
Hikma Pharmaceuticals PLC has a positive free cash flow as per the latest annual Cash flow statement released by the company. Positive free cash flow is cruscial for the financial health of a company, which can be used to pay dividends, expand operations, and deleverage its balance sheet (i.e., reduce debt).
HIK Cash Flow Statement History
Following table shows the history of Cash Flow Statements sheet for Hikma Pharmaceuticals PLC (LSE:HIK).
| 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 | |
|---|---|---|---|---|
| Total Cash From Operating Activities | 585,000,000 | 608,000,000 | 564,000,000 | 436,000,000 |
| Capital Expenditures | [object Object] | [object Object] | [object Object] | [object Object] |
| Investing Cash Flow | -607,000,000 | -333,000,000 | -381,000,000 | -388,000,000 |
| Financing Cash Flow | -58,000,000 | -337,000,000 | -188,000,000 | -25,000,000 |
| Free Cash Flow | 360,000,000 | 404,000,000 | 329,000,000 | 119,000,000 |
| Stock Based Compensation | 22,000,000 | 25,000,000 | 27,000,000 | 23,000,000 |
| Net Short Term Debt Issuance | 17,000,000 | -30,000,000 | -24,000,000 | -8,000,000 |
| Repayment Of Debt | -1,325,000,000 | -1,308,000,000 | -947,000,000 | -2,450,000,000 |
| Net Issuance Payments Of Debt | 456,000,000 | -93,000,000 | 124,000,000 | 301,000,000 |
| Issuance Of Capital Stock | - | - | -38,000,000 | -36,000,000 |
| Taxes Refund Paid | -55,000,000 | -129,000,000 | -125,000,000 | -124,000,000 |
| Net P P E Purchase And Sale | -137,000,000 | -151,000,000 | -165,000,000 | -197,000,000 |
| Change In Other Current Liabilities | -22,000,000 | 8,000,000 | 40,000,000 | 40,000,000 |
| Long Term Debt Issuance | 1,401,000,000 | 778,000,000 | 684,000,000 | 2,402,000,000 |
| Beginning Cash Position | ||||
| End Cash Position | ||||
| Changes In Cash | ||||
| Other Non Cash Items | ||||
| Common Stock Dividend Paid | ||||
| Change In Other Current Assets | ||||
| Cash Dividends Paid | ||||
| Gain Loss On Investment Securities | ||||
| Effect Of Exchange Rate Changes | ||||
| Issuance Of Debt | ||||
| Gain Loss On Sale Of P P E | - | - | ||
| Long Term Debt Payments | ||||
| Purchase Of P P E | ||||
| Operating Cash Flow | 585,000,000 | 608,000,000 | 564,000,000 | 436,000,000 |
| Capital Expenditure | -225,000,000 | -204,000,000 | -235,000,000 | -317,000,000 |
| Net Income From Continuing Operations |